Hyodeoxycholic acid attenuates atherosclerosis by antagonizing FXR and modulating the PD-1/mTORC1 signaling axis - PubMed
4 hours ago
- #Atherosclerosis
- #Treg migration
- #Hyodeoxycholic acid
- Hyodeoxycholic acid (HDCA) attenuates atherosclerosis by antagonizing FXR and modulating PD-1/mTORC1 signaling.
- Serum HDCA levels are significantly reduced in patients with atherosclerosis.
- HDCA therapy reduces plaque burden and enhances Treg migration and accumulation in plaques.
- HDCA reprograms Treg metabolism by increasing glycolysis and ATP production, improving migratory capacity and effector function.
- ZNF671 is identified as a transcriptional inhibitor of Treg migration, mitigated by HDCA-dependent metabolic switching.
- The HDCA-FXR-PD-1/mTORC1 axis is a novel immunometabolic target for atherosclerosis.